Phase II Trial of Cetuximab and Dasatinib in Patients With Cetuximab-resistant, Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck and Low Serum IL-6
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2018
At a glance
- Drugs Cetuximab (Primary) ; Dasatinib
- Indications Head and neck cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 02 Nov 2016 Status changed from recruiting to discontinued.
- 13 Jan 2015 Planned End Date changed from 1 May 2014 to 1 May 2017 according to ClinicalTrials.gov record.